Zhuzhou Qianjin Pharmaceutical (600479.SH): Dydrogesterone tablets and other products are expected to be selected for national centralized drug procurement.

Zhuzhou Qianjin Pharmaceutical (600479.SH) announced that on July 31, 2026, the company and its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., participated in the bidding process for the 12th batch of national centralized drug procurement organized by the National Organization for Drug Procurement. The company and Qianjin Xiangjiang Pharmaceutical aim to include four products, including Dydrogesterone Tablets, in this centralized procurement. This drug centralized procurement is the 12th national round organized by the government, which requires medical institutions to prioritize the use of selected products and ensure that the agreed procurement volume is met. If the company subsequently signs procurement contracts and implements them, it will be beneficial for these products to quickly penetrate the domestic market, increase market share, enhance the companys brand influence, and have a positive impact on the company's future operations.